|
2012 First Quarter Disclosure
2012.05.17
|
|---|
|
Daehan New Pharm Co., Ltd., Despite Decreased Sales and Profit, Strengthens Internal Stability
Daehan New Pharm Co., Ltd. reported a first-quarter sales revenue of 10,777 million KRW, a 15.9% decrease compared to the same period last year, and an operating profit of 1,075 million KRW (operating profit margin of 10.0%), down 28.1%. The main reason for the reduced performance compared to last year’s quarter was the absence of special demand for disinfectants worth 2,153 million KRW due to foot-and-mouth disease starting at the end of 2010, which had boosted results in the first quarter of 2011. Excluding this special demand factor, sales and operating profit remained at similar levels. Since the second half of 2011, Daehan New Pharm has been promoting the "Start-up Daehan New Pharm Project," focusing on strengthening business competitiveness and profitability and restructuring products and distribution channels, improving the quality aspect of sales.
In preparation for the drug price reduction and FTA enforcement starting from April 2012, Daehan New Pharm is strengthening its focus and specialization on core competencies and areas where multinational corporations or large pharmaceutical companies do not participate, such as obesity solutions. The company plans to continuously enhance its unique product structure and increase customer assets through direct transactions and distribution efficiency strategies. Through this business portfolio structure, the company aims to absorb the impact of drug price reductions while promoting differentiated strategies to become a small but strong enterprise. |


Home